What caused the pre-market spike in VANTABIO.BO stock today?

The pre-market **19.41%** rise to **₹20.30** on 20 Feb 2026 reflects thin liquidity, short-covering and intraday momentum. No public material corporate news was in filings; check company disclosures for contract wins or management updates before trading.

How does Meyka AI rate VANTABIO.BO stock and what does it mean?

Meyka AI rates VANTABIO.BO **60.46/100 (Grade B — HOLD)**. The grade balances sector comparison, financial metrics and forecasts. It is informational only and not a recommendation; perform your own due diligence.

What are the key valuation metrics for VANTABIO.BO stock to watch?

Watch EPS **-6.84**, trailing PE **-2.97**, PB **0.75**, market cap **₹144,373,600**, and debt-to-equity **1.59**. These show negative profitability but low book valuation; liquidity and cash flow are primary concerns.

What short-term technical levels matter for VANTABIO.BO stock?

Keep an eye on support near **₹20.30** (current) and resistance at the 50-day **₹22.99** and upper Bollinger **₹23.76**. RSI **33.08** and ATR **1.13** suggest volatile moves; use tight stops on intraday trades.

IN Stocks

VANTABIO.BO Vanta Bioscience BSE up 19.41% pre-market 20 Feb 2026: watch ₹22.99

ByDanny Kontos February 20, 2026February 20, 2026

VANTABIO.BO stock jumped 19.41% in the BSE pre-market on 20 Feb 2026, trading at ₹20.30 up from the previous close of ₹17.00 on light volume of 750 shares. The move places Vanta Bioscience Limited (VANTABIO.BO) among early top gainers in the Healthcare sector in India. The rally follows thin liquidity, a low float and the stock trading below its 50-day average of ₹22.99, creating a short-term battleground between momentum traders and value seekers. We examine fundamentals, technical signals and Meyka AI’s model outlook to frame actionable insights for today’s pre-market session.